Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer
Clinical trial NCT05243524 · TERMINATED
Trial details
- NCT number
- NCT05243524
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-05
- Primary completion
- 2023-07-24
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.